Previous Article | Next Article ![]()
Journal of Virology, August 2001, p. 7018-7029, Vol. 75, No. 15
Sir William Dunn School of Pathology,
University of Oxford, Oxford OX1 3RE, United Kingdom
Received 26 February 2001/Accepted 8 May 2001
A characterization of the A45R gene from vaccinia virus (VV) strain
Western Reserve is presented. The open reading frame is predicted to
encode a 125-amino-acid protein (Mr, of 13,600)
with 39% amino acid identity to copper-zinc superoxide dismutase
(Cu-Zn SOD). Sequencing of the A45R gene from other orthopoxviruses, here and by others, showed that the protein is highly conserved in all
viruses sequenced, including 16 strains of VV, 2 strains of cowpox
virus, camelpox virus, and 4 strains of variola virus. In all cases the
protein lacks key residues involved in metal ion binding that are
important for the catalytic activity. The A45R protein was expressed in
Escherichia coli, purified, and tested for SOD activity,
but neither enzymatic nor inhibitory SOD activity was detected.
Additionally, no virus-encoded SOD activity was detected in infected
cells or purified virions. A monoclonal antibody raised against the
A45R protein expressed in E. coli identified the A45R gene
product as a 13.5-kDa protein that is expressed late during VV
infection. Confocal microscopy of VV-infected cells indicated that the
A45R protein accumulated predominantly in cytoplasmic viral factories.
Electron microscopy and biochemical analyses showed that the A45R
protein is incorporated into the virion core. A deletion mutant lacking
the majority of the A45R gene and a revertant virus in which the
deleted gene was restored were constructed and characterized. The
growth properties of the deletion mutant virus were indistinguishable
from those of wild-type and revertant viruses in all cell lines tested,
including macrophages. Additionally, the virulence and pathogenicity of the three viruses were also comparable in murine and rabbit models of
infection. A45R is unusual in being the first VV core protein described
that affects neither virus replication nor virulence.
Vaccinia virus (VV) is the most
extensively studied member of the poxvirus family, a group of large DNA
viruses that replicate in the cell cytoplasm (37). It
contains a double-stranded DNA genome encoding about 200 proteins
(19, 27). Many of these proteins are essential for virus
growth in tissue culture; these include enzymes required for virus
replication in the cytoplasm and structural proteins needed for the
formation of the two infectious forms of the virus, the intracellular
mature virus (IMV) and the extracellular enveloped virus (EEV)
(6, 24). Other proteins, mostly encoded by genes located
near the ends of the virus genome, facilitate virus replication in vivo
or interfere with host immune functions. The latter group deals with
nonspecific immune mechanisms, such as complement, interferon, and the
inflammatory response, which are induced rapidly and constitute the
first host response against the invading organism. Additionally, VV
expresses proteins that block apoptosis and an enzyme
(3 The A45R open reading frame (ORF), previously called SalF8R in VV
strain Western Reserve (WR), is predicted to encode a 13.6-kDa protein
with 39% amino acid identity with copper-zinc superoxide dismutase
(Cu-Zn SOD) (51), an enzyme that catalyzes the conversion of superoxide to oxygen and hydrogen peroxide (35). There
are three known forms of SOD that contain either Mn, Fe, or both Cu and
Zn. The MnSODs are found in prokaryotes and in the matrix of
mitochondria, the FeSODs are present in prokaryotes and in a few
families of plants, and the Cu-Zn SODs occur primarily in the cytosol
of eukaryotic cells and in chloroplasts but have also been found in a
few species of bacteria. All SODs catalyze the same reaction with high
efficiency, and all operate by a similar mechanism in which the metal
is the catalytic factor in the active site (reviewed in reference
18). The cytosolic Cu-Zn SOD is a dimeric metalloprotein
composed of identical, noncovalently linked subunits, each of 16 kDa.
However, mammalian extracellular fluids contain a tetrameric
glycosylated Cu-Zn SOD. The three-dimensional structure of Cu-Zn SOD
shows the protein to contain eight antiparallel Superoxide radicals arise during numerous oxidations in both living and
nonliving systems and can act directly as oxidants or generate other
reactive products that are toxic to cells, causing damage to lipid
membranes, nucleic acid, carbohydrates, and proteins. To overcome this
problem, life forms have developed an effective defensive system,
including SOD, which scavenges active oxygen species generated during
aerobic metabolism. Consequently, aerobic existence is accompanied by a
persistent state of oxidative siege, and the survival of a given cell
is determined by its balance of reactive oxygen intermediates and
antioxidants. Disturbance of this balance can lead to disease
(20). Superoxide is also generated deliberately by
professional phagocytes (neutrophils, eosinophils, and macrophages)
during the respiratory burst to kill microorganisms (7,
58). In the case of activated neutrophils, the superoxide
released also produces a chemotaxin by reacting with a component of
blood plasma (42), allowing one activated neutrophil to
recruit others and thus to produce local inflammation. Therefore, a VV
SOD activity might be advantageous by enhancing virus survival in, and
in the presence of, phagocytes.
The nucleotide sequence of the A45R ORF has been determined in VV
strains WR (51), Copenhagen (19), modified
virus Ankara (MVA) (5), and Tian Tan (GenBank accession
number AAF34056); in variola major virus strains Harvey
(1), Bangladesh 1975 (33), and India 1967 (49); and in variola minor virus strain Garcia 1966 (50). It is highly conserved, showing more than 96% amino
acid identity. Alignment of the amino acid sequences of Cu-Zn SODs with
those from VV and variola virus indicates that although the viral
protein is predicted to contain the eight strands of antiparallel
In this report, a characterization of the A45R gene of VV strain WR is
provided. We show that the gene is highly conserved in all
orthopoxviruses tested, is expressed late during infection, and encodes
a protein that is present in the viral core. We also show that the
protein expressed in Escherichia coli does not have SOD
activity. The role of the A45R gene in VV biology was investigated by
deleting the gene from the virus genome and analyzing the biological effect in culture and in infected mice and rabbits.
Cells and viruses.
Monkey kidney BSC-1 and CV-1 cells,
rabbit kidney (RK)13 cells, HeLa cells, and D980R cells (a
hypoxanthine phosphoribosyltransferase [HPRT]-negative HeLa
derivative) were obtained from the Cell Bank of the Sir William Dunn
School of Pathology (University of Oxford, Oxford, United Kingdom). The
monocyte-macrophage cell lines P388D1 (mouse) and U937 (human) were
kindly provided by S. Gordon (Sir William Dunn School of Pathology).
Cells were grown in minimal essential medium (MEM) (GIBCO) supplemented
with 10% fetal bovine serum (FBS), except for D980R cells and the
monocyte-macrophage cell lines (P388D1 and U937), for which Dulbecco's
modified Eagle's medium (DMEM) (GIBCO) and RPMI 1640 (GIBCO) with 10%
FBS were used, respectively. The growth conditions and the sources of
VV strains and other orthopoxviruses have been described previously (2, 3). Working stocks of virus were prepared by Dounce homogenization of infected BSC-1 cells, removal of nuclei by
centrifugation, and sedimentation of virus in the supernatant through a
sucrose cushion as described elsewhere (32). Virus
infectivity was titrated by plaque assay on BSC-1 cells
(32). IMV and EEV were prepared from infected BSC-1 or
RK13 cells by sedimentation through sucrose gradients as
described elsewhere (41).
Sequencing of the A45R ORF in other orthopoxviruses.
A
fragment containing the entire A45R ORF plus 81 nucleotides upstream
and 126 nucleotides downstream was amplified by PCR using DNA extracted
from cells infected with different orthopoxviruses as the template and
the oligonucleotides
5'-GCGGGGATCCGGCACCACCAGTAACCGCGTAC-3' and
5'-GCGCGTCGACTTTGTCCCTATCAAATTCGACAG-3' (the
BamHI and SalI restriction sites, respectively,
are underlined), based on the VV WR strain sequence. The PCR products
(generated from multiple PCRs to avoid potential PCR errors) were
sequenced using the same primers and the ABI PRISM dye terminator cycle
sequencing ready reaction kit. Samples were run on an automatic ABI 373 DNA sequencer, and DNA sequences were analyzed by using the University
of Wisconsin Genetics Computer Group (GCG) program package, version
9.0.
Plasmid constructions. (i) Plasmids used for constructing
recombinant viruses.
A 2.4-kb EcoRI fragment containing
the A45R gene and flanking sequences was excised from the
SalI F fragment of VV WR (pSalIF) (51) and was
cloned into EcoRI-cut pUC119 to form plasmid pFAT1. The same
fragment was also cloned into EcoRI-cut pSJH7
(23), containing the E. coli guanine
phosphoribosyltransferase (Ecogpt) gene under the control of the VV 7.5 promoter. The resulting plasmid, termed pFAT2, was used to generate the
A45R revertant virus by transient dominant selection (TDS)
(16).
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.15.7018-7029.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
The Vaccinia Virus Superoxide Dismutase-Like
Protein (A45R) Is a Virion Component That Is Nonessential for
Virus Replication

and
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
-hydroxysteroid dehydrogenase [3
-HSD]) that synthesizes
steroid hormones and contributes to VV virulence (reviewed in reference
52).
-strands with a
Greek key topology and three protruding loops of nonrepetitive
structure, one of which binds the Zn atom (54).
-structure and a similar overall globular structure, it lacks the
Zn-binding region located near the C terminus and the majority of
histidine residues necessary for ion binding. These observations make
it unlikely that this protein has SOD activity, but it is quite
possible that the comparable protein in other VV strains or other
orthopoxviruses might be active.
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
(ii) Plasmids for expression of A45R in bacteria. Plasmid pFAT8 was used to express a thioredoxin-A45R fusion protein in E. coli. A DNA fragment containing the A45R ORF and terminal BamHI sites was amplified by PCR from pFAT1 DNA using oligonucleotides 5'-GCGCGGATCCATGGCTGTTTGTATAATAGACC-3' and 5'-GCGCGGATCCTCAAACGCCATTCTCGTTAATTG-3' as primers (the BamHI sites are underlined, and the initiation and termination codons are boldfaced). The PCR fragment was digested with BamHI and cloned into BglII-cut pThioHis C (His-Patch ThioFusion Expression System; Invitrogen, BV) to form pFAT8. The nucleotide sequence of the cloned PCR fragment was verified by DNA sequencing.
Construction of A45R deletion mutant and revertant viruses.
A VV deletion mutant lacking 60% of the A45R ORF was isolated by TDS
using the Ecogpt gene as the transient selectable marker (16) as described elsewhere (29). CV-1 cells
were infected with VV strain WR at 0.05 PFU/cell and transfected with
pFAT6. Progeny virus was plated onto monolayers of BSC-1 cells in the presence of mycophenolic acid (MPA). After a further round of plaque
purification under this selection, MPA-resistant viruses were resolved
to wild-type virus (vWTA45R) and A45R deletion virus (v
A45R) by
plating onto D980R cells in the presence of 6-thioguanine (25,
28). vWTA45R and v
A45R viruses were plaque purified twice
more. The revertant virus, in which the A45R locus was restored to that
of wild-type virus, was constructed using TDS as described above.
Plasmid pFAT2 was transfected into CV-1 cells infected with v
A45R,
and after isolation of MPA-resistant intermediate viruses, a revertant
virus (vRA45R) was isolated on D980R cells in the presence of
6-thioguanine.
A45R, and vRA45R were analyzed
by Southern blotting and PCR and were found to be as predicted.
Expression of the A45R ORF in E. coli.
The A45R
ORF was expressed as a thioredoxin fusion protein using the His-Patch
Thiofusion Expression System (Invitrogen, BV) according to the
manufacturer's specifications with some modifications. Plasmid pFAT8
was transformed into E. coli TOP 10 cells, and expression of
the thioredoxin-A45R fusion protein was induced with 1 mM
isopropyl-
-D-thiogalactopyranoside (IPTG) for 6 h
at 30°C. Cells from a 50-ml culture were pelleted, resuspended in 10 ml of 20 mM sodium phosphate (pH 7.8), and lysed by three
sonication-freeze-thaw cycles. Insoluble cellular material was removed
by centrifugation (at 3,000 × g for 15 min at 4°C), and the soluble fusion protein was purified by application to a 2-ml
Ni2+ column (ProBond) as instructed by the manufacturer. An
imidazole gradient was unable to elute the protein, so 50 mM EDTA was
used instead. The purified fusion protein was dialyzed against
phosphate-buffered saline (PBS) prior to quantification by the
bicinchoninic acid (BCA) (Pierce) protein assay. Finally, to overcome
the possible loss of metal ions during the purification process, the
purified fusion protein was reconstituted by simultaneous addition of
Cu2+ and Zn2+ in solution as described
previously (26).
Activity assay for SOD.
The SOD activities of the purified
A45R fusion protein, VV-infected cells, and IMV particles were measured
using the SOD assay kit (Calbiochem) according to the manufacturer's
instructions. BSC-1, RK13, HeLa, P388D1, and U937 cells
(5 × 106) were mock infected or infected with
vWTA45R, v
A45R, or vRA45R at 10 PFU/cell. Cells were harvested at
14 h postinfection (p.i.), pelleted, resuspended in 250 µl of
water, and lysed by three cycles of freeze-thawing. After
centrifugation (at 15,000 × g for 10 min at 4°C) the
supernatant was collected, treated with 400 µl of ice-cold
ethanol-chloroform at a 62.5/37.5 (vol/vol) ratio, and centrifuged at
3,000 × g for 5 min at 4°C, and different amounts of
the resulting supernatant were used in the SOD assay. The same treatment was performed for 150 µg of highly purified IMV particles. In all cases, the SOD assay was carried out in triplicate and bovine
Cu-Zn SOD was used as a standard.
Generation of MAbs against A45R. Murine monoclonal antibodies (MAbs) specific for A45R were obtained by standard procedures (21). BALB/c mice, 8 to 12 weeks old, were immunized subcutaneously with 50 µg of purified thioredoxin-A45R fusion protein in complete Freund's adjuvant, followed by similar injections in incomplete Freund's adjuvant at 4-week intervals. After a final boost, the spleen cells were fused with mouse hypoxanthine-aminopterin-thymidine (HAT)-sensitive NS1/1 myeloma cells and the resultant hybridomas were screened for A45R-specific antibody by indirect immunofluorescence and immunoblotting. After three cycles of cloning by limiting dilution, a clone that secreted an A45R-reactive antibody was selected and called MAb 2.B.11. This MAb was purified over a protein A-Sepharose column (Sigma) according to the manufacturer's specifications. The subclass of MAb 2.B.11 was identified as immunoglobulin G2a (IgG2a) using an immunoglobulin typing kit (Sigma).
Virus growth curves. Confluent monolayers of different cell lines were infected at either 0.01 or 10 PFU/cell. After 1 h, the inoculum was removed, and the monolayers were first washed three times with PBS and then overlaid with either MEM containing 2.5% FBS or RPMI supplemented with 10% FBS. At different times p.i., the cells were scraped into the growth medium, freeze-thawed three times, and sonicated, and the infectivity was titrated on BSC-1 cells.
Production of IMV and EEV was determined as follows. Cell monolayers were infected with 10 PFU/cell. After 24 h, the culture supernatant was removed and centrifuged to pellet detached cells, and the supernatant was retained as the EEV fraction. To obtain the IMV fraction, cells were scraped into MEM or RPMI containing 2.5 or 10% FBS, respectively, added to the pelleted cells from above, lysed by three freeze-thaw cycles, and sonicated. Virus titers were determined by plaque assay on BSC-1 cells in duplicate.Western blot analysis.
BSC-1 cells (106) were
mock infected or infected with the appropriate viruses at 10 PFU/cell
and maintained for 18 h in the presence or absence of 40 µg of
cytosine arabinoside (araC)/ml. Cells were harvested, collected by
centrifugation, resuspended in 200 µl of Laemmli buffer with
(reducing conditions) or without (nonreducing conditions)
2-
-mercaptoethanol (2-ME), and sonicated to shear DNA. Proteins were
separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and transferred electrophoretically to nitrocellulose
membranes (56). After being blocked for 1 h at room
temperature (RT) with TBS (20 mM Tris-HCl-500 mM NaCl [pH 7.5])
containing 3% (wt/vol) nonfat dry milk, blots were probed with the
purified anti-A45R (
-A45R) MAb 2.B.11 (diluted 1/10,000) in TTBS
(TBS-0.2% Tween 20), 1% (w/v) nonfat dry milk. Rabbit polyclonal
antisera against the VV protein BIR (diluted 1/2,500) (8)
or F13L (diluted 1/100,000) (22) or the murine MAb AB1.1 against the D8L gene product (diluted 1/2,500) (41) was
used as a control in some experiments. The blots were then incubated with horseradish peroxidase-conjugated goat
-mouse or
-rabbit Ig
(Sigma) diluted 1/2,000 in TTBS-1% nonfat dry milk for 1 h at
RT, and the immune complexes were detected using the enhanced chemiluminescence (ECL) detection system (Amersham) according to the
manufacturer's instructions. For analysis of virion proteins, 20 µg
of purified IMV and EEV particles was resolved by SDS-PAGE, transferred
to nitrocellulose membranes, and immunoblotted as above.
Indirect immunofluorescence staining for conventional and
confocal microscopy.
Subconfluent BSC-1 cells grown on glass
coverslips were infected at 1 PFU/cell. At different times p.i., cells
were washed in ice-cold PBS and fixed by incubation with 4%
paraformaldehyde (PFA) in 250 mM HEPES (pH 7.4) for 10 min on ice,
followed by 40 min at RT in 8% PFA in the same buffer. Cells were then
washed with PBS, permeabilized with 0.2% Triton X-100 for 15 min at
RT, and treated for 20 min at RT with PBS containing 20 mM glycine. After being washed in PBS, cells were incubated in blocking solution (PBS, 1% bovine serum albumin [BSA], 0.2% fish skin gelatin [pH 8]) for 1 h at RT, incubated with the purified
-A45R MAb
2.B.11 (diluted 1/250) in blocking solution for 1 h at RT, washed
extensively with blocking solution, and then incubated with fluorescein
isothiocyanate (FITC)-conjugated goat
-mouse Ig (Sigma) at a 1/320
dilution in blocking solution for 30 min at RT. The cells were rinsed
three times in PBS and once in water, and then the coverslips were
mounted in Mowiol containing 1 µg of 4',6'-diamidino-2-phenylindole
(DAPI)/ml. Samples were analyzed with an Axiophot microscope (Zeiss).
Confocal microscopy was performed using a Bio-Rad MCR 1024 laser
scanning microscope, and images were collected and processed with
COMOS-7 and Adobe Photoshop software.
Fractionation of IMV by detergent treatment. Viral envelopes were separated from the cores as described previously (14) with some modifications. Purified IMV (1010 particles) was disaggregated by sonication and incubated in lysis buffer (1% NP-40, 50 mM Tris-HCl, 5 mM MgCl2 [pH 7.9]) for 30 min at RT. After centrifugation at 13,000 × g for 15 min at 4°C, the supernatant containing the membrane protein fraction was collected. The pellet was resuspended in lysis buffer containing 50 mM dithiothreitol (DTT) and incubated for 30 min at RT, and then the soluble fraction (membrane protein-NP-40-DTT fraction) was released from the cores by centrifugation under the same conditions. The cores were treated with 1% NP-40-0.5% sodium deoxycholate-0.1% SDS at 4°C for 30 min, and the solubilized core fraction was separated from the insoluble fraction by centrifugation at 13,000 × g for 15 min at 4°C. Samples were resolved by SDS-PAGE, transferred to nitrocellulose membranes, and immunoblotted as above.
Electron microscopy. (i) Immunogold labeling and negative
staining of purified IMV particles.
Carbon-coated nickel 400-mesh
grids were glow discharged and floated on 108 PFU of
purified IMV particles for 5 min at RT. The grids were washed with PBS
and fixed by incubation with 4% PFA in 250 mM HEPES (pH 7.4) for 45 min at RT. After being washed in PBS, the samples were either
permeabilized with 0.2% Triton X-100 in PBS for 15 min at RT or not
permeabilized and treated for 20 min at RT with PBS containing 20 mM
glycine. Virus-coated grids were blocked with 3% BSA-0.45% fish skin
gelatin in PBS (pH 8) (blocking solution) for 1 h at RT, incubated
with the purified
-A45R MAb 2.B.11 (diluted 1/25) in blocking
solution for 1 h at RT, and washed extensively with PBS. Bound Ig
was detected by incubation for 1 h at RT with
colloidal-gold-conjugated rabbit
-mouse Ig (BioCell) diluted 1/10 in
blocking solution. The murine MAb C3 against A27L (diluted 1/25)
(44) was used as a control in some experiments. After a
final wash with PBS, samples were fixed in PBS containing 2.5%
glutaraldehyde and washed in double-distilled water, and virus
particles were negatively stained with 2.5% uranyl acetate. Samples
were examined in a Zeiss Omega 912 electron microscope (LEO Electron
Microscope Ltd., Oberkochen, Germany). Digital images were captured
with the integrated Soft Imaging Software (SIS) image package (SIS
Imaging Software, GmbH, Munster, Germany) and were processed using
Adobe Photoshop software.
(ii) Immunogold labeling of thin sections of purified IMV. Purified IMV particles were pelleted by centrifugation for 40 min at 14,000 × g in a Eppendorf centrifuge and then were fixed with 8% PFA in 250 mM HEPES (pH 7.4) for 1 h at RT. After being washed in PBS, the pellet was incubated for 20 min with 20 mM glycine in PBS, dehydrated in a graded ice-cold ethanol series, and embedded in LR White (polymerization for 12 h at 56°C; London Resin Company), and ultrathin sections on nickel grids were immunolabeled and analyzed as described above.
Virulence assays. (i) Murine intranasal model. Female BALB/c mice (5 to 6 weeks old) weighing between 15 and 20 g were anesthetized and infected intranasally with either 104, 105, or 106 PFU per animal in 25 µl of PBS (61). Mice were weighed daily and monitored for signs of illness. Animals that had lost more than 30% of their original body weight were sacrificed by cervical dislocation. Virus infectivity in different organs was determined by plaque assay on BSC-1 cells.
(ii)Murine intradermal model. Female BALB/c mice (8 weeks old) were anesthetized and injected intradermally in the left ear pinnae with either 104, 105, or 106 PFU per animal in 10 µl of PBS. The diameters of lesions produced on infected ears were determined daily using a micrometer. Virus titers in ears at different times after inoculation were determined as described previously (57).
(iii) Rabbit skin model. A female New Zealand White rabbit (weighing 1.5 kg) was inoculated subcutaneously along the left and right flanks with either 104, 105, or 106 PFU/site in 100 µl of PBS. The diameters of lesions produced were determined daily. For histological examination of VV-induced lesions, a similar experiment was carried out, in which the rabbit was sacrificed 3 days after inoculation.
Statistical analysis. Student's t test was used to test for the significance of the results (P < 0.05).
Nucleotide sequence accession numbers. The nucleotide sequences presented in this paper have been assigned GenBank accession numbers AF349002, AF349003, AF349004, AF349005, AF349006, AF349006, AF349007, AF349008, AF349009, AF349010, AF349011, AF349012, AF349013, AF3749014, AF349015, and AF349016.
| |
RESULTS |
|---|
|
|
|---|
The A45R gene is conserved in orthopoxviruses. The A45R gene in the WR strain of VV is located within the HindIII A fragment at the right end of the VV genome. The sequence of the A45R gene predicts a primary translation product of 125 amino acids with a molecular size of 13.6 kDa and an estimated isoelectric point of 6.5. The protein does not contain any potential signal peptide or transmembrane anchor sequence. As noted previously, A45R is predicted to encode a polypeptide with 39% amino acid identity with Cu-Zn SODs from eukaryotic sources (51).
Nucleotide sequence data are available for the A45R gene of several VV and variola virus strains (see the introduction). The predicted protein sequence is highly conserved among these viruses, but comparison with eukaryotic Cu-Zn SODs indicated that A45R might not function as a SOD (51). Therefore, we investigated if the gene is conserved in other orthopoxviruses, and in particular, whether the missing regions at the C terminus are present. The nucleotide sequences of the A45R genes from 12 strains of VV, cowpox virus (Brighton Red strain), elephantpox virus (considered a cowpox virus strain), and camelpox virus were determined. Alignment of the deduced amino acid sequences showed that A45R is highly conserved (94 to 100% amino acid identity) and has the same length in each virus with the exception of VV strains MVA (containing a deletion of amino acids 27 to 30) and Tashkent (containing a base insertion near the 3' end of the gene that produces a frameshift so that the last 12 amino acids are absent and are replaced by an unrelated sequence of 7 amino acids, NNTFSYN). In all cases, the protein lacked the Zn-binding region of loop 6, 5 and the loop 7, 8 near the C terminus. However, the highly conserved nature of the A45R gene suggests that it might have an important function in the virus life cycle.The A45R protein expressed in E. coli does not have SOD
activity.
To characterize biochemically the A45R protein and to
produce greater amounts of protein for functional analysis and antibody production, the protein was expressed as a fusion protein in an IPTG-inducible bacterial vector and purified to near-homogeneity by
chromatography on a nickel agarose resin (see Materials and Methods).
Expression of large amounts of soluble fusion protein was possible only
when the induction step was carried out at 30°C, the affinity
purification was performed in the absence of NaCl, and elution from the
nickel column was done with 50 mM EDTA (see Materials and Methods). As
shown in Fig. 1A,
bacteria carrying the pFAT8 plasmid
expressed an abundant polypeptide of 25 kDa after, but not before,
induction with IPTG. Because two cysteine residues are present in the
amino acid sequence of A45R, we investigated whether the
affinity-purified fusion protein formed disulfide-bonded dimers. The
purified protein was boiled in Laemmli buffer with (reducing
conditions) or without (nonreducing conditions) 2-ME and was analyzed
by SDS-PAGE, but the migration of the protein was unaltered (Fig. 1B).
|
Disruption of the A45R gene in the virus genome.
To help
identify and to study the function of the A45R gene product in the
virus life cycle, a deletion mutant virus lacking 60% of the ORF
(v
A45R), a plaque-purified wild-type virus (vWTA45R), and a
revertant virus (vRA45R) were constructed (see Materials and Methods).
The genome structures of the recombinant viruses were analyzed by
Southern blotting and PCR and were shown to be as predicted. In
addition, expression of the A44L and A46R genes was analyzed by Western
and Northern blotting respectively, and no differences were detected
among the three viruses (data not shown). Finally, the absence of A45R
expression by v
A45R was demonstrated by immunoblotting extracts from
cells infected with this virus (see below). Collectively, these data
showed that the recombinant viruses have the predicted genome
structures and gene expression patterns.
A45R is not essential for virus growth in culture.
Isolation
of the deletion mutant virus v
A45R showed that the A45R gene is
dispensable for virus replication in vitro. In fact, the size and
morphology of plaques formed by v
A45R on BSC-1 cells were
indistinguishable from those of vWTA45R and vRA45R (Fig.
2A). Nevertheless, it was possible that
there were differences in the virus yield that would not be reflected
in plaque size. To test this possibility, the growth kinetics of these
viruses were compared. After infection of BSC-1 cells at 0.01 PFU/cell (Fig. 2B) or 10 PFU/cell (data not shown), no differences in
total-virus yields were detected for the three viruses. To compare the
amounts of IMV and EEV produced by these viruses, BSC-1 cells were
infected at 10 PFU/cell and the virus in the cells or supernatant was
determined at 24 h p.i. as described in Materials and Methods.
Similar titers were produced by v
A45R, vWTA45R, and vRA45R (Fig.
2C), confirming that loss of the A45R gene did not affect the
production of normal amounts of either IMV or EEV. The three viruses
also share similar growth characteristics after infection of CV-1,
RK13, HeLa, and D980R cells (data not shown).
|
A45R, vWTA45R and vRA45R were
analyzed in murine resident peritoneal macrophages or bone marrow-derived macrophages, and in the mouse or human
monocyte-macrophage cell lines P388D1 and U937, respectively. After
infection with 0.01 or 10 PFU/cell, no virus production was detected in
either peritoneal or bone marrow-derived murine macrophages. In
contrast, virus replication was observed in P388D1 and U937 cells, but
the yields of infectious virus were indistinguishable for the three viruses (data not shown).
Overall, these results indicate that the A45R gene is dispensable for
replication of VV in tissue culture and does not lead to a host range
restriction on any of the monkey, rabbit, or human cell lines tested.
The A45R gene encodes a 13.5-kDa polypeptide expressed late during
VV infection.
The nucleotide sequence of the WR A45R gene revealed
a potential late transcriptional start site (TAAAT) (15)
close to the initiation codon, suggesting that the gene might be
expressed late during infection. To investigate this experimentally,
the expression of A45R protein in VV-infected cells was analyzed by Western blotting using the A45R-specific MAb 2.B.11. Parallel blots
were probed with a rabbit polyclonal antiserum against the B1R protein
(8) to show that virus-specific protein was present in all
samples (data not shown). Extracts from BSC-1 cells 18 h after
infection with vWTA45R and vRA45R contained a protein of 13.5 kDa that
was present only in the absence of araC and was absent from uninfected
cells and cells infected with v
A45R (Fig. 3). In addition, there was a minor
higher-molecular-size polypeptide (~65 kDa) also recognized by the
MAb 2.B.11 that might represent A45R oligomers. In the absence of
reducing agents, no differences in the electrophoretic mobility or in
the protein pattern were detected (Fig. 3), suggesting that the
putative A45R oligomers are not due to the formation of disulfide
bonds. Finally, analysis of the proteins present in the tissue culture
supernatant of VV-infected cells indicated that A45R protein was not
secreted from the cell (data not shown).
|
Subcellular localization of A45R protein in VV-infected cells.
The intracellular localization of A45R during VV infection was
determined by confocal microscopy (Fig.
4). In cells infected with either vWTA45R
or vRA45R, the A45R protein was distributed diffusely throughout the
nucleus and cytoplasm of infected cells but showed a more intense
staining pattern in perinuclear cytoplasmic regions that colocalized
with the viral DNA factories, which were visualized by DAPI staining
(Fig. 4). In addition, MAb 2.B.11 decorated punctate structures
throughout the cell, which probably represent individual virus
particles. In cells infected with v
A45R no staining was detected,
demonstrating the specificity of MAb 2.B.11. As a control,
immunofluorescence analysis was carried out with MAb AB1.1, which
recognizes the D8L protein, and identical staining patterns were
observed for the three viruses (data not shown).
|
A45R protein is encapsidated and localizes in the viral core.
To investigate whether the A45R protein was present in virus particles,
vWTA45R, v
A45R, and vRA45R were grown in RK13 cells and
IMV was purified by sucrose density gradient centrifugation. Virus
proteins were then analyzed in parallel with extracts of vWTA45R-infected cells by immunoblotting with MAb 2.B.11 (Fig. 5). Proteins of 13.5 and 65 kDa were
detected in infected cells and in IMV particles from vWTA45R and vRA45R
but not in IMV particles from v
A45R. The absence of the 65-kDa
polypeptide in mock-infected cells and in IMV particles from v
A45R
indicates that it is A45R specific. As in the case of infected-cell
extracts, the presence or absence of reducing agents did not alter the
electrophoretic mobility or pattern of virion proteins. Whether the
high-molecular-weight product is a homo- or a heteromultimeric complex
is not known. The blot was stripped and reprobed with MAb AB1.1 against
the IMV protein D8L to confirm equivalent protein loading. The purity of IMV preparations was confirmed by probing the blot with anti-F13L antibody, which recognizes an EEV-specific protein (22).
These data demonstrate that A45R is incorporated into virus particles.
|
A45R IMV
particles were not labeled with MAb 2.B.11, suggesting that the A45R
protein is not exposed on the virion surface. In contrast, vWTA45R and
v
A45R particles were labeled by MAb C3 against the VV A27L protein,
which is exposed on the surface of the virion (data not shown)
(53). When IMV particles were permeabilized by treatment
with Triton X-100 to allow the antibody access to epitopes protected by
the virus envelope, immunogold labeling of vWTA45R IMV but not of
v
A45R IMV was observed, suggesting that the A45R protein is
associated with the viral core.
|
A45R IMV was observed.
Finally, to confirm the subviral localization of A45R protein,
virions were treated with NP-40 in the presence or absence of DTT to
release detergent-soluble membrane proteins from the cores, and these
were partitioned further into soluble and insoluble fractions by
treatment with deoxycholate and SDS. Fractions were then analyzed by
SDS-PAGE and immunoblotting with antibodies against D8L, L4R, and A45R.
The detection of the VV D8L protein in the membrane fraction and L4R in
the core fraction demonstrated the effectiveness of the fractionation
(data not shown). Both the 13.5- and 65-kDa A45R proteins were retained
in the core after NP-40-DTT fractionation and were recovered in the
deoxycholate-SDS-soluble fraction of the core (Fig. 6C).
Analysis of SOD activity in VV-infected cells and purified IMV
particles.
Although the A45R protein expressed in E. coli did not exhibit either SOD activity or inhibitory activity
toward bovine Cu-Zn SOD, it was possible that this protein did not have
the correct folding to allow functional activity. Therefore, SOD
activity assays were performed with extracts of BSC-1,
RK13, HeLa, P388D1, and U937 cells 14 h after
infection with vWTA45R, v
A45R, or vRA45R. No differences in SOD
activity were detected in mock-infected or virus-infected cells (data
not shown). Since the A45R protein is incorporated into virions,
similar experiments were carried out with purified IMV particles, and
neither SOD activity nor inhibitory activity was detected (data not
shown). These data indicate that the WR A45R protein does not have SOD
activity or any effect on the cellular SOD, at least in the cells and
under the conditions analyzed.
Virulence of VV lacking the A45R gene.
To determine if the
A45R gene affects virulence, the outcome of infection with v
A45R was
compared to that with vWTA45R and vRA45R in a murine intranasal model
(61). Virulence was assessed by weight loss and signs of
illness (piloerection, arched back, and reduced mobility). Animals
infected with each virus at doses of 105 or 106
PFU per animal all suffered severe weight loss and signs of illness and
were sacrificed by day 6 p.i. (data not shown). At 104 PFU
there were no significant differences in the amount of weight loss or
the rate of recovery between mice infected with the different viruses
(Fig. 7A), but mice infected with
v
A45R showed slightly higher signs of illness on days 6 to 8 compared with mice infected with either vWTA45R or vRA45R (Fig. 7B).
Statistical analysis using the unpaired Student's t test
found a significant difference (P = 0.048) between the
mean values for the v
A45R-infected group and each other group on day
7 only. Since the difference is significant only on 1 day and the
P value is just within the limit, it is very difficult to
conclude, at least in this model, that A45R plays any role in
virulence. However, when the number of animals presenting severe signs
of illness at different times p.i. was plotted (Fig. 7C), an early
onset of severe signs in v
A45R-infected animals was observed,
suggesting a possible effect of A45R on the outcome of infection.
|
A45R was then analyzed in a murine intradermal
model (57). In this model, inoculation of VV strain WR into the ear pinnae leads to a localized and limited infection where
virus spread is minimal and the mice suffer no signs of systemic
illness. Groups of six animals were injected intradermally in the left
ear pinnae with doses of 104, 105, or
106 PFU of either vWTA45R, v
A45R, or vRA45R/ear, and the
diameters of resulting lesions were measured daily. Figure 7D shows
that animals infected with these viruses at 104 PFU/ear did
not present significant differences in lesion size. Identical results
were obtained at doses of 105 and 106 PFU/ear
(data not shown). In a second experiment, the titers of infectious
virus in ears at different times p.i. and the cellular and humoral
immune responses were determined as described previously (57). There was no significant difference in virus titer
or in cellular and humoral immune response after infections with the
different viruses (data not shown). Finally, the role of the A45R gene
in virulence was assessed in a rabbit skin model. For this purpose, a
New Zealand White rabbit was inoculated subcutaneously along the left
and right flanks with either vWTA45R, v
A45R, or vRA45R at
104, 105, or 106 PFU/site, and the
diameters of lesions produced were determined daily. As described for
the murine intradermal model, there was no difference in size among the
lesions produced by the three viruses (data not shown). A histological
examination of virus-induced lesions in both models was performed, and
again no differences were detected among the different viruses (data
not shown). These results show that, at least in the last two models,
the A45R gene does not contribute to virus virulence.
| |
DISCUSSION |
|---|
|
|
|---|
VV and other poxviruses express a wide variety of proteins that are nonessential for virus replication in vitro but help the virus to evade the host response to infection. In this paper we have characterized the VV A45R protein, which shares 39% amino acid identity with eukaryotic Cu-Zn SOD. Data presented show that the A45R protein is expressed late during infection and is incorporated into IMV particles but lacks SOD activity. A virus with a disrupted A45R gene replicated normally in vitro and had unaltered virulence in mice and rabbits.
The A45R gene was selected for study because VV virulence might be influenced by the presence of SOD, an enzyme that provides defense against damage caused by superoxide radicals (18). This enzyme could be used by poxviruses to avoid the toxic effects of UV light and protect against the DNA-, lipid-, and protein-damaging effects of reactive oxygen species. Furthermore, vertebrate macrophages and neutrophils produce superoxide radicals as a means of killing invading microorganisms (7, 58). Therefore, a virus-encoded SOD activity might induce virus resistance to destruction by an oxidative burst when the virus enters macrophages either after phagocytosis or as part of its replicative cycle.
Published sequence data for four strains of VV and four strains of variola virus showed that the A45R protein is highly conserved and shares more than 96% amino acid identity. However, the protein has lost some surface peptide loops and the Zn-binding domain that are critical for SOD activity (51), suggesting that it was unlikely to have SOD activity. Nonetheless, it was possible that the A45R protein might be active in other VV strains or other orthopoxviruses. There are precedents for a VV gene being functional in some VV strains but not others. For instance, an active tumor necrosis factor receptor is expressed by 3 out of 16 VV strains (4). Therefore, the A45R gene was sequenced in 12 additional VV strains, camelpox virus, and cowpox virus. The protein was highly conserved, but in all cases the two major deletions affecting residues critical for SOD activity were present. In agreement with sequence data, no SOD activity was detected for the protein expressed in E. coli (Fig. 1) or in extracts of virus-infected cells in comparison with extracts of uninfected or deletion mutant virus-infected cells, or in purified virus particles.
Within the Poxviridae, proteins related to SOD are present in the leporipoxviruses myxoma virus (12) and Shope fibroma virus (60), the molluscipoxvirus molluscum contagiosum virus (48), and the entomopoxvirus B Amsacta moorei virus (9). Sequence analysis revealed that all have deletions or substitutions within the coding region that are likely to render the protein inactive, with the exception of Amsacta moorei virus, where the SOD protein appears to be intact. However, no SOD activity has been reported for the entomopoxvirus protein. Potential SODs have also been identified in other complex DNA viruses including baculovirus (55) and the chlorella virus PBCV-1, a member of the Phycodnaviridae family (30). However, SOD activity in these proteins remains to be demonstrated. It is interesting that members of the Baculoviridae, Poxviridae, and Phycodnaviridae families, which have significantly different replication strategies, carry SOD-like proteins.
The presence of a complete SOD in entomopoxvirus and baculovirus might
reflect a function for SOD in viruses replicating in insect hosts, and
perhaps this activity might have been lost during the evolution of
vertebrate poxviruses. Alternatively, it is possible that poxviruses
use a nonfunctional SOD-like protein to inhibit or regulate cellular
SOD function or for some other purpose. For instance, the regulation of
cellular SOD in poxvirus-infected cells might disrupt the balance of
oxidants and antioxidants. Further, since oxidative stress can induce
apoptosis (11), this may aid virus dissemination.
Additionally, an increase in the cellular oxidant status results in
activation of transcriptional factors, such as NF-
B
(46), that may be necessary for replication of some
viruses. For instance, the Tat protein from human immunodeficiency virus type 1 induces the activation of NF-
B, which is important for
virus replication, by down-regulation of cellular MnSOD
(59). Another example is the Epstein-Barr virus, which
induces autoantibodies against cellular MnSOD, thus contributing to
viral pathogenesis (43).
An A45R-specific MAb was isolated and was used to identify the A45R protein in VV-infected cells as a major 13.5-kDa polypeptide that was expressed late during infection, consistent with the presence of the TAAAT motif (15) close to the translational start site. Additionally, a minor higher-molecular-size polypeptide of about 65 kDa was detected. The presence of this high-molecular-weight protein might be explained by postranslational modifications of the 13.5-kDa protein, or by the formation of homo- or hetero-oligomeric structures. Although no disulfide-bonded oligomers were detected, many of the glycine residues involved in the formation of cellular SOD homodimers (40) are conserved in A45R. Further study is required to address the nature of this 65-kDa protein.
Immunofluorescence microscopy showed that the A45R protein was distributed widely in the nuclei and cytosol of infected cells. Interestingly, a similar pattern was described for eukaryotic Cu-Zn SODs (13). Small proteins (up to 50 kDa) can diffuse passively through the nuclear pore, whereas proteins destined for active nuclear import possess specific nuclear localization signals (NLSs) that are recognized by protein import receptors (34). A45R and Cu-Zn SODs do not have NLSs, suggesting that either they diffuse through the nuclear pore due to their small size, they contain unknown NLSs, or they interact with other proteins that contain NLSs.
The presence of the A45R protein in the core fraction of viral particles was demonstrated by Western blotting and immunogold labeling of purified virus particles. This was evident from labeling of thin sections and permeabilized particles, and the absence of labeling of the surface of intact IMV. These data were consistent with the biochemical data that showed that the protein was present in the soluble fraction of the core. Interestingly, the 65-kDa protein detected in infected cells was also incorporated into the IMV core. This polypeptide is recognized specifically by the MAb, and therefore it is likely to be the result of the interaction of A45R with itself or with other cellular or viral proteins. A study of VV protein-protein interactions by two-hybrid analysis has been reported recently (36). This analysis indicated that A45R interacts with itself, with A4L, a virion protein that localizes between the core and IMV membrane (14), and with J1R, another virion protein that forms homodimers (5). Further study of these interactions in vivo and their functions in the virus life cycle is needed.
The high conservation of the A45R gene in all orthopoxviruses analyzed and the association of the protein with viral particles suggest an important role during VV infection. To address the essentiality and function of A45R, a recombinant virus lacking the majority of the A45R gene was constructed and compared with wild-type and revertant viruses. The growth properties, plaque phenotype, and infectious intra- and extracellular virus yields of the deletion mutant virus were indistinguishable from those of the wild-type and revertant viruses in all cell lines tested, including monocyte-macrophage cell lines. Additionally, A45R was found to play no role in virus virulence in either a murine or a rabbit intradermal model. In a murine intranasal model, a possible early onset of signs of illness was detected after infection with the deletion mutant, suggesting a possible function of A45R in the progression of the infection.
This very limited, if any, role of A45R in virulence makes A45R the first example of a VV structural protein that is nonessential for virus replication in vitro and in vivo. There are other structural VV proteins that are nonessential in vitro, but in all cases a role in virulence has been reported. For instance, D8L and A56R (virus hemagglutinin), membrane proteins of IMV and EEV particles, respectively, are nonessential for virus replication in vitro, but the deletion or disruption of these genes produces virus attenuation in vivo (17, 31, 39, 45). It is possible that the A45R gene appears to be nonessential because its function is compensated for by other viral or host proteins. Despite the A45R gene being unnecessary for virus replication in monocyte-macrophage cell lines, the protein could be important for viral replication in resting macrophages in vivo. We have shown that the WR strain of VV does not replicate in primary macrophage cultures, consistent with previous reports (10, 38). This abortive infection might be due to the disruption in VV strain WR of the gene related to p28 of ectromelia virus, which is critical for in vitro replication of ectromelia virus in murine resident peritoneal macrophages (47). Further studies with VV strains that encode a complete p28 might elucidate the possible function of A45R during VV replication in macrophages. Alternatively, the protein may play a role in some circumstances that we have not studied, such as in an alternate host, or after exposure to extremes of temperature or UV light. Experiments to investigate some of these possibilities are in progress.
| |
ACKNOWLEDGMENTS |
|---|
We thank Francisco Iborra and Ana Pombo for advice and assistance with electron and confocal microscopy, Pike Pucklevic for help with generation of MAbs, and Sara Thompson for tissue culture.
This work was supported by grants from The Wellcome Trust and the United Kingdom Medical Research Council. F.A. was the recipient of a long-term EMBO fellowship, D.C.T. was a Wellcome Trust Traveling Fellow, and G.L.S. is a Wellcome Trust Principal Research Fellow.
| |
FOOTNOTES |
|---|
* Corresponding author. Present address: The Wright-Fleming Institute, Imperial College School of Medicine, St. Mary's Campus, Norfolk Place, London W2 1PG, United Kingdom. Phone: 44-207-594-3972. Fax: 44-207-594-3973. E-mail: glsmith{at}ic.ac.uk.
Present address: Centro Nacional de Biotecnología, Consejo
Superior de Investigaciones Científicas, Department of
Molecular and Cell Biology, Campus Universidad Autónoma,
Cantoblanco, 28049 Madrid, Spain.
Present address: Laboratory of Viral Diseases, NIAID, NIH,
Bethesda, MD 20892.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Aguado, B.,
I. P. Selmes, and G. L. Smith.
1992.
Nucleotide sequence of 21.8 kbp of variola major virus strain Harvey and comparison with vaccinia virus.
J. Gen. Virol.
73:2887-2902 |
| 2. | Alcamí, A., and G. L. Smith. 1995. Vaccinia, cowpox, and camelpox viruses encode soluble gamma interferon receptors with novel broad species specificity. J. Virol. 69:4633-4639[Abstract]. |
| 3. |
Alcamí, A.,
J. A. Symons,
P. D. Collins,
T. J. Williams, and G. L. Smith.
1998.
Blockade of chemokine activity by a soluble chemokine binding protein from vaccinia virus.
J. Immunol.
160:624-633 |
| 4. | Alcamí, A., A. Khanna, N. L. Paul, and G. L. Smith. 1999. Vaccinia virus strains Lister, USSR and Evans express soluble and cell-surface tumour necrosis factor receptors. J. Gen. Virol. 80:949-959[Abstract]. |
| 5. | Antoine, G., F. Scheiflinger, F. Dorner, and F. G. Falkner. 1998. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244:365-396[CrossRef][Medline]. |
| 6. |
Appleyard, G.,
A. J. Hapel, and E. A. Boulter.
1971.
An antigenic difference between intracellular and extracellular rabbitpox virus.
J. Gen. Virol.
13:9-17 |
| 7. | Babior, B. M. 1987. The respiratory burst oxidase. Trends Biochem. Sci. 12:241-243. |
| 8. | Banham, A. H., and G. L. Smith. 1992. Vaccinia virus gene B1R encodes a 34-kDa serine/threonine protein kinase that localizes in cytoplasmic factories and is packaged into virions. Virology 191:803-812[CrossRef][Medline]. |
| 9. | Bawden, A. L., K. J. Glassberg, J. Diggans, R. Shaw, W. Farmerie, and R. W. Moyer. 2000. Complete genomic sequence of the Amsacta moorei entomopoxvirus: analysis and comparison with other poxviruses. Virology 274:120-139[CrossRef][Medline]. |
| 10. | Broder, C. C., P. E. Kennedy, F. Michaels, and E. A. Berger. 1994. Expression of foreign genes in cultured human primary macrophages using recombinant vaccinia virus vectors. Gene 142:167-174[CrossRef][Medline]. |
| 11. | Buttke, T. M., and P. A. Sandstrom. 1994. Oxidative stress as a mediator of apoptosis. Immunol. Today 15:7-10[CrossRef][Medline]. |
| 12. | Cameron, C., S. Hota-Mitchell, L. Chen, J. Barrett, J. X. Cao, C. Macaulay, D. Willer, D. Evans, and G. McFadden. 1999. The complete DNA sequence of myxoma virus. Virology 264:298-318[CrossRef][Medline]. |
| 13. |
Crapo, J. D.,
T. Oury,
C. Rabouille,
J. W. Slot, and L. Y. Chang.
1992.
Copper,zinc superoxide dismutase is primarily a cytosolic protein in human cells.
Proc. Natl. Acad. Sci. USA
89:10405-10409 |
| 14. |
Cudmore, S.,
R. Blasco,
R. Vincentelli,
M. Esteban,
B. Sodeik,
G. Griffiths, and J. Krijnse Locker.
1996.
A vaccinia virus core protein, p39, is membrane associated.
J. Virol.
70:6909-6921 |
| 15. | Davison, A. J., and B. Moss. 1989. Structure of vaccinia virus late promoters. J. Mol. Biol. 210:771-784[CrossRef][Medline]. |
| 16. |
Falkner, F. G., and B. Moss.
1990.
Transient dominant selection of recombinant vaccinia viruses.
J. Virol.
64:3108-3111 |
| 17. | Flexner, C., A. Hugin, and B. Moss. 1987. Prevention of vaccinia virus infection in immunodeficient mice by vector-directed IL-2 expression. Nature 330:259-262[CrossRef][Medline]. |
| 18. | Fridovich, I. 1995. Superoxide radical and superoxide dismutases. Annu. Rev. Biochem. 64:97-112[CrossRef][Medline]. |
| 19. | Goebel, S. J., G. P. Johnson, M. E. Perkus, S. W. Davis, J. P. Winslow, and E. Paoletti. 1990. The complete DNA sequence of vaccinia virus. Virology 179:247-266[CrossRef][Medline]. |
| 20. | Halliwell, B., and J. M. C. Gutteridge. 1999. Free radicals in biology and medicine, 3rd ed. Oxford University Press, Oxford, United Kingdom. |
| 21. | Harlow, E., and D. Lane. 1988. Antibodies: a laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. |
| 22. |
Hirt, P.,
G. Hiller, and R. Wittek.
1986.
Localization and fine structure of a vaccinia virus gene encoding an envelope antigen.
J. Virol.
58:757-764 |
| 23. |
Hughes, S. J.,
L. H. Johnston,
A. de Carlos, and G. L. Smith.
1991.
Vaccinia virus encodes an active thymidylate kinase that complements a cdc8 mutant of Saccharomyces cerevisiae.
J. Biol. Chem.
266:20103-20109 |
| 24. | Ichihashi, Y., S. Matsumoto, and S. Dales. 1971. Biogenesis of poxviruses: role of A-type inclusions and host cell membranes in virus dissemination. Virology 46:507-532[CrossRef][Medline]. |
| 25. | Isaacs, S. N., G. J. Kotwal, and B. Moss. 1990. Reverse guanine phosphoribosyltransferase selection of recombinant vaccinia viruses. Virology 178:626-630[CrossRef][Medline]. |
| 26. | Jewett, S. L., G. S. Latrenta, and C. M. Beck. 1982. Metal-deficient copper-zinc superoxide dismutases. Arch. Biochem. Biophys. 215:116-128[CrossRef][Medline]. |
| 27. | Johnson, G. P., S. J. Goebel, and E. Paoletti. 1993. An update on the vaccinia virus genome. Virology 196:381-401[CrossRef][Medline]. |
| 28. | Kerr, S. M., and G. L. Smith. 1991. Vaccinia virus DNA ligase is nonessential for virus replication: recovery of plasmids from virus-infected cells. Virology 180:625-632[CrossRef][Medline]. |
| 29. | Kettle, S., N. W. Blake, K. M. Law, and G. L. Smith. 1995. Vaccinia virus serpins B13R (SPI-2) and B22R (SPI-1) encode Mr 38.5 and 40K, intracellular polypeptides that do not affect virus virulence in a murine intranasal model. Virology 206:136-147[CrossRef][Medline]. |
| 30. | Lu, Z., Y. Li, Q. Que, G. F. Kutish, D. L. Rock, and J. L. Van Etten. 1996. Analysis of 94 kb of the chlorella virus PBCV-1 330-kb genome: map positions 88 to 182. Virology 216:102-123[CrossRef][Medline]. |
| 31. |
Maa, J. S.,
J. F. Rodriguez, and M. Esteban.
1990.
Structural and functional characterization of a cell surface binding protein of vaccinia virus.
J. Biol. Chem.
265:1569-1577 |
| 32. | Mackett, M., G. L. Smith, and B. Moss. 1985. The construction and characterization of vaccinia virus recombinants expressing foreign genes, p. 191-211. In D. M. Glover (ed.), DNA cloning: a practical approach, vol. 2. IRL Press, Oxford, United Kingdom. |
| 33. | Massung, R. F., L. I. Liu, J. Qi, J. C. Knight, T. E. Yuran, A. R. Kerlavage, J. M. Parsons, J. C. Venter, and J. J. Esposito. 1994. Analysis of the complete genome of smallpox variola major virus strain Bangladesh-1975. Virology 201:215-240[CrossRef][Medline]. |
| 34. | Mattaj, I. W., and L. Englmeier. 1998. Nucleocytoplasmic transport: the soluble phase. Annu. Rev. Biochem. 67:265-306[CrossRef][Medline]. |
| 35. |
McCord, J. M., and I. Fridovich.
1969.
Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein).
J. Biol. Chem.
244:6049-6055 |
| 36. |
McCraith, S.,
T. Holtzman,
B. Moss, and S. Fields.
2000.
Genome-wide analysis of vaccinia virus protein-protein interactions.
Proc. Natl. Acad. Sci. USA
97:4879-4884 |
| 37. | Moss, B. 1996. Poxviridae: the viruses and their replication, p. 2637-2671. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, 3rd ed, vol. 2. Lippincott-Raven Publishers, Philadelphia, Pa. |
| 38. | Natuk, R. J., and J. A. Holowczak. 1985. Vaccinia virus proteins on the plasma membrane of infected cells. III. Infection of peritoneal macrophages. Virology 147:354-372[CrossRef][Medline]. |
| 39. |
Niles, E. G., and J. Seto.
1988.
Vaccinia virus gene D8 encodes a virion transmembrane protein.
J. Virol.
62:3772-3778 |
| 40. |
Parge, H. E.,
R. A. Hallewell, and J. A. Tainer.
1992.
Atomic structures of wild-type and thermostable mutant recombinant human Cu,Zn superoxide dismutase.
Proc. Natl. Acad. Sci. USA
89:6109-6113 |
| 41. | Parkinson, J. E., and G. L. Smith. 1994. Vaccinia virus gene A36R encodes a Mr 43-50 K protein on the surface of extracellular enveloped virus. Virology 204:376-390[CrossRef][Medline]. |
| 42. |
Petrone, W. F.,
D. K. English,
K. Wong, and J. M. McCord.
1980.
Free radicals and inflammation: superoxide-dependent activation of a neutrophil chemotactic factor in plasma.
Proc. Natl. Acad. Sci. USA
77:1159-1163 |
| 43. |
Ritter, K.,
R. J. Kuhl,
F. Semrau,
H. Eiffert,
H. D. Kratzin, and R. Thomssen.
1994.
Manganese superoxide dismutase as a target of autoantibodies in acute Epstein-Barr virus infection.
J. Exp. Med.
180:1995-1998 |
| 44. |
Rodriguez, J. F.,
R. Janeczko, and M. Esteban.
1985.
Isolation and characterization of neutralizing monoclonal antibodies to vaccinia virus.
J. Virol.
56:482-488 |
| 45. |
Rodriguez, J. R.,
D. Rodriguez, and M. Esteban.
1992.
Insertional inactivation of the vaccinia virus 32-kilodalton gene is associated with attenuation in mice and reduction of viral gene expression in polarized epithelial cells.
J. Virol.
66:183-189 |
| 46. |
Schreck, R.,
P. Rieber, and P. A. Baeuerle.
1991.
Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF- B transcription factor and HIV-1.
EMBO J.
10:2247-2258[Medline].
|
| 47. | Senkevich, T. G., E. J. Wolffe, and R. M. Buller. 1995. Ectromelia virus RING finger protein is localized in virus factories and is required for virus replication in macrophages. J. Virol. 69:4103-4111[Abstract]. |
| 48. | Senkevich, T. G., J. J. Bugert, J. R. Sisler, E. V. Koonin, G. Darai, and B. Moss. 1996. Genome sequence of a human tumorigenic poxvirus: prediction of specific host response-evasion genes. Science 273:813-816[Abstract]. |
| 49. | Shchelkunov, S. N., V. M. Blinov, and L. S. Sandakhchiev. 1993. Genes of variola and vaccinia viruses necessary to overcome the host protective mechanisms. FEBS Lett. 319:80-83[CrossRef][Medline]. |
| 50. | Shchelkunov, S. N., A. V. Totmenin, V. N. Loparev, P. F. Safronov, V. V. Gutorov, V. E. Chizhikov, J. C. Knight, J. M. Parsons, R. F. Massung, and J. J. Esposito. 2000. Alastrim smallpox variola minor virus genome DNA sequences. Virology 266:361-386[CrossRef][Medline]. |
| 51. |
Smith, G. L.,
Y. S. Chan, and S. T. Howard.
1991.
Nucleotide sequence of 42 kbp of vaccinia virus strain WR from near the right inverted terminal repeat.
J. Gen. Virol.
72:1349-1376 |
| 52. | Smith, G. L., J. A. Symons, A. Khanna, A. Vanderplasschen, and A. Alcamí. 1997. Vaccinia virus immune evasion. Immunol. Rev. 159:137-154[CrossRef][Medline]. |
| 53. | Sodeik, B., S. Cudmore, M. Ericsson, M. Esteban, E. G. Niles, and G. Griffiths. 1995. Assembly of vaccinia virus: incorporation of p14 and p32 into the membrane of the intracellular mature virus. J. Virol. 69:3560-3574[Abstract]. |
| 54. | Tainer, J. A., E. D. Getzoff, J. S. Richardson, and D. C. Richardson. 1983. Structure and mechanism of copper, zinc superoxide dismutase. Nature 306:284-287[CrossRef][Medline]. |
| 55. | Tomalski, M. D., R. Eldridge, and L. K. Miller. 1991. A baculovirus homolog of a Cu/Zn superoxide dismutase gene. Virology 184:149-161[CrossRef][Medline]. |
| 56. |
Towbin, H.,
T. Staehelin, and J. Gordon.
1979.
Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.
Proc. Natl. Acad. Sci. USA
76:4350-4354 |
| 57. |
Tscharke, D. C., and G. L. Smith.
1999.
A model for vaccinia virus pathogenesis and immunity based on intradermal injection of mouse ear pinnae.
J. Gen. Virol.
80:2751-2755 |
| 58. | Weiss, S. J. 1986. Oxygen, ischemia and inflammation. Acta Physiol. Scand. Suppl. 548:9-37. |
| 59. |
Westendorp, M. O.,
V. A. Shatrov,
K. Schulze-Osthoff,
R. Frank,
M. Kraft,
M. Los,
P. H. Krammer,
W. Droge, and V. Lehmann.
1995.
HIV-1 Tat potentiates TNF-induced NF- B activation and cytotoxicity by altering the cellular redox state.
EMBO J.
14:546-554[Medline].
|
| 60. | Willer, D. O., G. McFadden, and D. H. Evans. 1999. The complete genome sequence of Shope (rabbit) fibroma virus. Virology 264:319-343[CrossRef][Medline]. |
| 61. |
Williamson, J. D.,
R. W. Reith,
L. J. Jeffrey,
J. R. Arrand, and M. Mackett.
1990.
Biological characterization of recombinant vaccinia viruses in mice infected by the respiratory route.
J. Gen. Virol.
71:2761-2767 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»